Diabetes Care. 2024; 48(Supplement_1):S181-S206.
PMID: 39651989
PMC: 11635045.
DOI: 10.2337/dc25-S009.
Wang C, Cai Y, Feng P
Front Immunol. 2024; 15:1405856.
PMID: 39450164
PMC: 11499202.
DOI: 10.3389/fimmu.2024.1405856.
Obata Y, Takemoto M, Sakaue T, Kawata S, Mukai K, Miyashita K
Diabetol Int. 2024; 15(3):605-610.
PMID: 39101180
PMC: 11291780.
DOI: 10.1007/s13340-024-00719-4.
Sugai K, Miwa T, Kojima J, Ueda Y, Tsukahara K, Nishi H
Endocrine. 2024; 85(2):593-597.
PMID: 38502365
PMC: 11291589.
DOI: 10.1007/s12020-024-03780-w.
Angelousi A, Ziogas D, Siampanopoulou V, Mytareli C, Anastasopoulou A, Lyrarakis G
Diseases. 2024; 12(2).
PMID: 38391787
PMC: 10887699.
DOI: 10.3390/diseases12020040.
Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus.
Wei H, Lai Y, Lin G, Lin C, Chang Y, Chang J
Diabetol Metab Syndr. 2024; 16(1):26.
PMID: 38254155
PMC: 10804587.
DOI: 10.1186/s13098-024-01263-6.
Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
Wu L, Carlino M, Brown D, Long G, Clifton-Bligh R, Mellor R
J Clin Endocrinol Metab. 2023; 109(5):1301-1307.
PMID: 37997380
PMC: 11031227.
DOI: 10.1210/clinem/dgad685.
Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus.
Shen M, Chen D, Zhao R, Zheng X, Gu Y, Yang T
Front Endocrinol (Lausanne). 2023; 14:1213225.
PMID: 37554766
PMC: 10405819.
DOI: 10.3389/fendo.2023.1213225.
Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.
Liu Y, Liu H, Zhao S, Chen K, Jin P
Front Immunol. 2023; 14:1164120.
PMID: 37359544
PMC: 10288983.
DOI: 10.3389/fimmu.2023.1164120.
Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn's disease: A case report.
Gao M, Xu Y, Wang W
World J Clin Cases. 2023; 11(14):3267-3274.
PMID: 37274046
PMC: 10237137.
DOI: 10.12998/wjcc.v11.i14.3267.
Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population-based cohort study.
Chan J, Lee S, Kong D, Lakhani I, Ng K, Dee E
Cancer Med. 2023; 12(7):8144-8153.
PMID: 36647331
PMC: 10134274.
DOI: 10.1002/cam4.5616.
Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice.
Rodriguez de Vera-Gomez P, Pinar-Gutierrez A, Guerrero-Vazquez R, Bellido V, Morales-Portillo C, Sancho-Marquez M
J Diabetes Res. 2022; 2022:4508633.
PMID: 36387939
PMC: 9652069.
DOI: 10.1155/2022/4508633.
Adult-onset autoimmune diabetes.
Buzzetti R, Maddaloni E, Gaglia J, Leslie R, Wong F, Boehm B
Nat Rev Dis Primers. 2022; 8(1):63.
PMID: 36138034
DOI: 10.1038/s41572-022-00390-6.
Editorial: Decoding checkpoint inhibitor-induced endocrinopathies.
Burnett D, Barnet M, Samaras K
Front Endocrinol (Lausanne). 2022; 13:987648.
PMID: 35966058
PMC: 9372577.
DOI: 10.3389/fendo.2022.987648.
Environmental Triggering of Type 1 Diabetes Autoimmunity.
Houeiss P, Luce S, Boitard C
Front Endocrinol (Lausanne). 2022; 13:933965.
PMID: 35937815
PMC: 9353023.
DOI: 10.3389/fendo.2022.933965.
Immune Checkpoint Inhibitor-related Endocrinopathies.
Lu D, Gao Y
J Transl Int Med. 2022; 10(1):9-14.
PMID: 35702188
PMC: 8997801.
DOI: 10.2478/jtim-2022-0009.
Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis.
Zhang Y, Fang Y, Wu J, Huang G, Bin J, Liao Y
Front Pharmacol. 2022; 13:817662.
PMID: 35431928
PMC: 9012537.
DOI: 10.3389/fphar.2022.817662.
Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series.
Ganta N, Alnabwani D, Keating S, Patel V, Bommu V, Dawoud R
Cureus. 2022; 14(2):e22070.
PMID: 35295363
PMC: 8916979.
DOI: 10.7759/cureus.22070.
When therapeutic drugs lead to diabetes.
Feve B, Scheen A
Diabetologia. 2022; 65(5):751-762.
PMID: 35244742
DOI: 10.1007/s00125-022-05666-w.
Pembrolizumab-Induced Type 1 Diabetes in a 95-Year-Old Veteran With Metastatic Melanoma.
Ng D, Weinreb J, Rumrill S
Fed Pract. 2022; 38(11):520-523.
PMID: 35136336
PMC: 8815611.
DOI: 10.12788/fp.0191.
